Home

Our vision is to provide effective patient positioning support and thereby address the healthcare sector's need to provide conditions that maintain skin integrity in a market where pressure ulcers are one of the most costly and fastest growing problems.

A platform of products backed by scientific evidence of superior effect over currently available products. We plan to set a new standard in both healthcare, and in other sectors where positioning conditions put patients at risk of developing pressure ulcers.

Our products will also be able to meet high sustainability goals at cost margins that enable profitable distribution in developing countries.

Pressure ulcers cost global healthcare an estimated $500 (€500) billion each year.
The cost within EU is between 4-5 % of the countries’ total healthcare budget.
In Sweden, the cost of treatment of a single pressure ulcer is around 1755 SEK (€160) per day.
Studies in Sweden and in other European countries show more than 1 in 5 patients in-hospital suffer from pressure ulcers.
Studies show that today’s pressure-preventive foam mattresses (standard of care) don’t adequately prevent pressure ulcers
In a best case scenario they marginally prolong the time before it they occur.
Advanced mechanized mattresses are somewhat more effective but very expensive and uncomfortable.
Only 4,4 % of patients that are considered to be in a risk group receive pressure-preventive treatment.
Treating pressure ulcers is up to ten times more expensive than preventing them.

Starfish of Sweden holds a patent granted by Swedish PRV on 11 April, 2023 with an international publication following. Our application process began with PRV as a seamless path to EU and USA filings. The process for additional international applications is in progress.

UN Sustainable Development Goals is a collection of independent but interconnected goals carefully designed to give all of us on our planet a better future, with hundreds of targets and measurement indicators geared toward a date of 2030. The goals were created with businesses in mind, providing a path – what some people refer to as a “Pathway for Humanity” — for any business to harness their power by directing their efforts toward specific global objectives.

The goals themselves to be simple and direct, but powerful, ranging from ending poverty to building sustainable cities. Any individual can find something on the diverse list of Sustainable Development Goals to work toward. Small and medium-sized businesses, however, are uniquely positioned to make significant impacts on the SDG targets.

SmiLe Incubator is a non-profit business incubator for life science startups. The vision is to enable a future of better health by nurturing a community of passionate life science innovators.

This is realized by offering our life science entrepreneurs with advanced coaching programs, well-equipped labs with state-of-the art instruments, a large international network of industry partners and investors, and a community of world-class life science innovators.

SmiLe Incubator does not take equity in the companies we support. Working on a no-equity, non-profit basis enables us to build a neutral platform for launching health innovation into the world.

Starfish of Sweden is developing an innovative, patent pending market platform to shield patients from conditions known to initiate pressure ulcers.

The idea and solution simplifies and disrupts repetitive, costly wound management by maintaining healthy skin conditions and patient comfort.

Micro-vascular circulation maintained by unique non-contacting patterns

Skin temperature & humidity reduction

Reduced shear & improved comfort by deformable self-activated “pillows”

Improved self-ventilation system

More effective than it is expensive

Integrates directly into standard practice and distribution

MDR class 1

Our vision is to provide effective patient positioning support and thereby address the healthcare sector's need to provide conditions that maintain skin integrity in a market where pressure ulcers are one of the most costly and fastest growing problems.

A platform of products backed by scientific evidence of superior effect over currently available products. We plan to set a new standard in both healthcare, and in other sectors where positioning conditions put patients at risk of developing pressure ulcers.

Our products will also be able to meet high sustainability goals at cost margins that enable profitable distribution in developing countries.

We are developing a product platform to minimize skin conditions initiating pressure ulcers primarily within category 1, and therefore indirectly, also more severe categories.

80% of the health care sectors cost (the largest market share) related to pressure ulcers are linked to category 1 and 2 pressure injury (below).

80% of the health care sectors cost (the largest market share) related to pressure ulcers are linked to category 1 and 2 pressure injury (below).

Our initial market is the healthcare sector where caregivers are highly receptive to improved patient support solutions and new alternatives to current products for which show limited success in prevention of pressure ulcers, or bedsores.

Pressure ulcers cost global healthcare an estimated $500 (€500) billion each year.

The cost within EU is between 4-5 % of the countries’ total healthcare budget.

In Sweden, the cost of treatment of a single pressure ulcer is around 1755 SEK (€160) per day.

Studies in Sweden and in other European countries show more than 1 in 5 patients in-hospital suffer from pressure ulcers.

Studies show that today’s pressure-preventive foam mattresses (standard of care) don’t adequately prevent pressure ulcers
In a best case scenario they marginally prolong the time before it they occur.

Advanced mechanized mattresses are somewhat more effective but very expensive and uncomfortable.

Only 4,4 % of patients that are considered to be in a risk group receive pressure-preventive treatment.

Treating pressure ulcers is up to ten times more expensive than preventing them.

Starfish of Sweden holds a patent granted by Swedish PRV on 11 April, 2023 with an international publication following. Our application process began with PRV as a seamless path to EU and USA filings. The process for additional international applications is in progress.

Member of SmiLe Incubator Medicon Village Lund

We think differently.

For more information please contact Jim Roslund

Chairman of the Board

Co-founder

Starfish of Sweden is developing an innovative, patent pending market platform to shield patients from conditions known to initiate pressure ulcers.

The idea and solution simplifies and disrupts repetitive, costly wound management by maintaining healthy skin conditions and patient comfort.

Micro-vascular circulation maintained by unique non-contacting patterns

Skin temperature & humidity reduction

Reduced shear & improved comfort by deformable self-activated “pillows”

Improved self-ventilation system

More effective than it is expensive

Integrates directly into standard practice and distribution

MDR class 1

Our vision is to provide effective patient positioning support and thereby address the healthcare sector's need to provide conditions that maintain skin integrity in a market where pressure ulcers are one of the most costly and fastest growing problems.

A platform of products backed by scientific evidence of superior effect over currently available products. We plan to set a new standard in both healthcare, and in other sectors where positioning conditions put patients at risk of developing pressure ulcers.

Our products will also be able to meet high sustainability goals at cost margins that enable profitable distribution in developing countries.

We are developing a product platform to minimize skin conditions initiating pressure ulcers primarily within category 1, and therefore indirectly, also more severe categories.

80% of the health care sectors cost (the largest market share) related to pressure ulcers are linked to category 1 and 2 pressure injury (below).

80% of the health care sectors cost (the largest market share) related to pressure ulcers are linked to category 1 and 2 pressure injury (below).

Our initial market is the healthcare sector where caregivers are highly receptive to improved patient support solutions and new alternatives to current products for which show limited success in prevention of pressure ulcers, or bedsores.

Pressure ulcers cost global healthcare an estimated $500 (€500) billion each year.

The cost within EU is between 4-5 % of the countries’ total healthcare budget.

In Sweden, the cost of treatment of a single pressure ulcer is around 1755 SEK (€160) per day.

Studies in Sweden and in other European countries show more than 1 in 5 patients in-hospital suffer from pressure ulcers.

Studies show that today’s pressure-preventive foam mattresses (standard of care) don’t adequately prevent pressure ulcers In a best case scenario they marginally prolong the time before it they occur.

Advanced mechanized mattresses are somewhat more effective but very expensive and uncomfortable.

Only 4,4 % of patients that are considered to be in a risk group receive pressure-preventive treatment.

Treating pressure ulcers is up to ten times more expensive than preventing them.

Starfish of Sweden holds a patent granted by Swedish PRV on 11 April, 2023 with an international publication following. Our application process began with PRV as a seamless path to EU and USA filings. The process for additional international applications is in progress.

Member of SmiLe Incubator Medicon Village Lund

We think differently. For more information please contact Jim Roslund

Chairman of the Board

Co-founder

Studies show that today’s pressure-preventive foam mattresses (standard of care) don’t adequately prevent pressure ulcers
In a best case scenario they marginally prolong the time before it they occur.

We think differently.

For more information please contact Jim Roslund